Cardiovascular morbidity remains the leading cause of death in the world, in both men and women. But the programs for the prevention of cardiovascular diseases (CVD), which significantly reduced the incidence of cardiovascular complications among men, proved to be ineffective among the female population. Differences in CVD risk factors in different sexes, different responses of the female and male organism to the same treatment effects induce, on the one hand, the development of gender-oriented cardiological practices and, on the other hand, determine the need to include gynecologists in the development and implementation of cardiovascular reduction measures vascular morbidity and mortality.

The concept of fetal programming implies the influence of factors of the external and internal environment in the intrauterine period on the epigenetic regulation of the genome, which leads to phenotypic changes in the fetus, as well as to postnatal diseases of man, manifesting throughout life. It is possible to improve the state of health, quality and life expectancy of offspring, as well as subsequent generations, due to the pregravidar preparation of both parents, the modification of their lifestyle, the abandonment of bad habits, the rationalization of nutrition, and the donation of vitamin and mineral complexes.

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS) with severe psycho-emotional disorders. The frequency of occurrence of PMDD in women of the reproductive period of the Russian Federation is estimated at an average of 15.6 %. The development of PMDD is based on the individual sensitivity of neurotransmitters and neuropeptides to fluctuations in the levels of sex steroid hormones of the ovulatory menstrual cycle, therefore, hormone therapy drugs are used for PMDD therapy — combined oral contraceptives (COC) that suppress ovulation.

The purpose of this study was to evaluate the effectiveness of COC containing drospirenone in the treatment of PMDD.

Materials and methods. 78 women of the reproductive period underwent a comprehensive examination and treatment of PMDD symptoms with contraceptives containing 30 mg of ethinyl estradiol and 3 mg of drospirenone (Midian).

Results of the study. The age of patients with PMDD averaged 33.7 years; 55 % of women were between 25–34 years old; 97 % needed contraception; all women represented in the group had higher education, normal menstrual function and body mass index. After 3 months of treatment, there was a statistically significant decrease in pain of various localization, problems with appetite, difficulties in communicating with others, sleep disturbances, and an increase in productivity at work, at home and in school. After 6 months of treatment, COC psycho-emotional symptoms, such as depression, anger, irritation, emotional lability, anxiety, tension, loss of control, significantly regressed, while the effectiveness of therapy reached 50 % relative to the original background. Physical symptoms of PMS, such as swelling of the mammary glands, pain of various locations, sleep disturbances, were stopped on average by 70 %.

Conclusions. COC containing drospirenone can be used to treat severe premenstrual syndrome, i. e. PMDD.

The purpose of the study was to evaluate the efficacy of treatment of recurrent drug Orungamin depending on the time of occurrence of relapse.

Material and methods. 62 women with recurrent candida vulvovaginit is were examined and treated. The mean age of the patients was 35.6 ± 0.7 years. The main group consisted of 32 patients who in the premenstrual period 5 days before the expected date of menstruation were prescribed Orungamin 1 capsule (100 mg) twice a day (200 mg) for 3 days during three consecutive menstrual cycles. The comparison group included women receiving Orungamin three consecutive cycle 3 day 1 capsule (100 mg) 2 times a day, without regard to days of the menstrual cycle.

Results. Therapy with Orungamin 100 mg twice a day during the premenstrual period not only helped to increase the effectiveness of the treatment of relapses, but also the quality of life of patients.

Objective: to evaluate the effectiveness of termination of pregnancy in the later stages of a combined method for congenital malformations of the fetus, incompatible with life. The prospective study involved 195 pregnant women, divided into two groups. The main group consisted of 98 women who underwent termination of pregnancy in the later periods by the following combined method. The comparison group included 97 women, abortion was carried out according to the WHO scheme. The effectiveness of the combined method of termination in late pregnancy in the main group was 99.0 % and 96.9 % in the comparison group.

Hormone therapy is an effective treatment option for menopausal women, although prolonged use of hormone therapy is associated with a slightly increased risk of breast cancer, thromboembolism, and stroke. A literature search for studies evaluating the effects of hormone therapy in menopausal women with asymptomatic fibroids demonstrated variable effects of hormone therapy on the volume and size of the fibroids. Some studies have demonstrated an increase in size of pre-existing asymptomatic fibroids and formation of new fibroids with higher doses of progestogen in combination therapy. Selective estrogen receptor modulators having tissue-specific estrogen agonistic and antagonistic actions such as raloxifene have a favorable clinical profile and may be better alternatives in women with asymptomatic fibroids.

The results of research testify the negative influence of epilepsy on the severity of menopausal disorders. We conducted a survey of 43 postmenopausal women with epilepsy using climacteric scale of Green. The survey revealed that in presence of epilepsy climacteric syndrome tends to a protracted course with a predominance of severe and moderate forms.

The article emphasizes the etiology, pathogenesis and complications of pelvic inflammatory diseases in the use of intrauterine contraceptives (IUD). The risk of inflammation is higher in the first weeks of the use of IUD. The urgency of the problem is shown by the example of the case from the practice of the gynecological department of Khujand regional clinical hospital (Republic of Tajikistan).

The somatic and gynecological status of women with uterine myoma is presented. A significantly high frequency of concomitant extragenital pathology was revealed, including: iron deficiency anemia, thyroid and urinary tract diseases, pathology of the gastrointestinal tract, obesity and varicose veins. It has been established that patients with uterine myoma often suffer from menstrual dysfunction of the type of hypermenstrual syndrome and algodimenorrhea, menometrorrhagia. More than half of the examined women with uterine myoma detected a combination of this pathology with endometrial hyperplasia, benign ovarian formations, pelvic inflammatory diseases, cystic fibrosis of the mammary glands.